Evidence map›Paper›PMID 26288822›Full record

ArticleEBioMedicine2015

Serum DHCR24 Auto-antibody as a new Biomarker for Progression of Hepatitis C.

Sayeh Ezzikouri, Kiminori Kimura, Hajime Sunagozaka, Shuichi Kaneko, Kazuaki Inoue, Tomohiro Nishimura, Tsunekazu Hishima, Michinori Kohara, Kyoko Tsukiyama-Kohara

Open access · goldAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in EBioMedicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Hepatitis C Virus: Viral Quasispecies and Genotypes.International journal of molecular sciences · 2017
    Review
  11. Article
  12. HCV-Induced Oxidative Stress: Battlefield-Winning Strategy.Oxidative medicine and cellular longevity · 2016
    Review
  13. Article
  14. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 7 institutions in 2 countries.

Sayeh EzzikouriVirology Unit, Viral Hepatitis Laboratory, Pasteur Institute of Morocco, Casablanca, Morocco ; Transboundary Animal Diseases Centre, Joint Faculty of Veterinary Medicine, Kagoshima University, Kagoshima, Japan ; Laboratory of Animal Hygiene, Joint Faculty of Veterinary Medicine, Kagoshima University, Kagoshima, Japan.
Kiminori KimuraDivision of Hepatology, The Tokyo Metropolitan Komagome Hospital, Tokyo, Japan.
Hajime SunagozakaDepartment of Gastroenterology, Graduate School of Medicine, Kanazawa University, Kanazawa, Japan.
Shuichi KanekoDepartment of Gastroenterology, Graduate School of Medicine, Kanazawa University, Kanazawa, Japan.
Kazuaki InoueDepartment of Gastroenterology, Showa University, Fujigaoka Hospital, Kanagawa, Japan.
Tomohiro NishimuraChemo-Sero Research Institute, Kyoku-shi, Kumamoto, Japan.
Tsunekazu HishimaDivision of Pathology, The Tokyo Metropolitan Komagome Hospital, Tokyo, Japan.
Michinori KoharaDepartment of Microbiology and Cell Biology, Tokyo Metropolitan Institute of Medical Science, Japan.
Kyoko Tsukiyama-KoharaTransboundary Animal Diseases Centre, Joint Faculty of Veterinary Medicine, Kagoshima University, Kagoshima, Japan ; Laboratory of Animal Hygiene, Joint Faculty of Veterinary Medicine, Kagoshima University, Kagoshima, Japan.
Kanazawa University · JPTokyo Metropolitan Komagome Hospital · JPInstitut Pasteur du Maroc · MAKagoshima University · JPKaketsuken (Japan) · JPShowa University Fujigaoka Hospital · JPTokyo Metropolitan Institute of Medical Science · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNew biomarkers are needed to identify the stage of hepatitis C virus (HCV)-infected diseases in order to reduce the mortality rates. Herein, we investigated whether serum 3β-hydroxysterol Δ24-reductase antibody (DHCR24 Ab) may serve as a prognostic marker for hepatitis C infection progression to hepatocellular carcinoma (HCC).

methodsSerum DHCR24 Abs from 395 HCV-positive patients, including 133 chronic hepatitis (CHC), 85 liver cirrhosis (LCC), and 177 HCC (HCC-C) patients; 232 hepatitis B virus (HBV)-positive patients, including 103 chronic hepatitis (CHB), 56 liver cirrhosis (LCB), and 73 HCC (HCC-B) patients; and 24 healthy controls, were measured using enzyme-linked immunosorbent assay.

resultsThe serum DHCR24 Ab levels were significantly higher in patients with CHC than in healthy controls, in LCC than in CHC, and in LCC than in HCC-C (P < 0.0001 for all). The concentration of serum DHCR24 Ab in HCC-B patients showed no significant difference compared to CHB and LCB patients (P = 0.1247). The DHCR24 Ab levels were significantly higher in early HCC-C than CHC or LCC patients and in late HCC-C compared to early HCC-C patients. The sensitivity of the DHCR24 Ab for HCC-C detection (70.6%) was higher than that of alpha-fetoprotein (AFP; 54.8%) and protein induced by vitamin K absence or antagonist-II (PIVKA-II; 42 · 5%). Moreover, DHCR24 was up-regulated in HCV-positive, but not HBV-positive tissues or HBV-negative, HCV-negative HCC specimens.

conclusionsDHCR24 auto-antibody represents a potential noninvasive biomarker for HCV-related liver disease and may facilitate the diagnosis of PIVKA-II and AFP-negative HCC.

Indexed as

Agedalpha-FetoproteinsAutoantibodiesBiomarkersBiomarkers, TumorCarcinoma, HepatocellularDisease ProgressionFemaleHepacivirusHepatitis C, ChronicHumansLiverLiver NeoplasmsMaleMiddle AgedNerve Tissue Proteinsacarboxyprothrombinalpha-FetoproteinsAutoantibodiesBiomarkersBiomarkers, TumorDHCR24 protein, humanNerve Tissue ProteinsOxidoreductases Acting on CH-CH Group DonorsProtein PrecursorsProthrombin3β-Hydroxysterol Δ24-reductase antibodyBiomarkerHepatitis C virusLiver cancerSerum autoantibody

Identifiers

PMID26288822
PMCPMC4535309
OpenAlexW2041268211

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.